What is MNKD's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.06B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for MNKD?

P/E (TTM) is n/a and 52-week range is $2.23 to $6.51 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s MNKD figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for MNKD?

The company profile lists revenue (TTM) near $407M, net income (TTM) near $-4.42B, EPS (TTM) near $-0.14 when available from the market-data feed. Figures are informational and may lag live markets.

Where is MannKind Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in Danbury, Connecticut, US, 319.4M shares outstanding, ISIN US56400P7069 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

MannKind Corp

$MNKD

Health Care · Biotechnology

IR Run Scenarios

$3.29

-3.80%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. The company is headquartered in Danbury, Connecticut and currently employs 592 full-time employees. The company went IPO on 2004-07-28. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Employees

592

Website

mannkindcorp.com/

IPO

2004-07-28

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)